AbbVie has been granted a patent for HIF-1a prolyl hydroxylase inhibitors, which can be used to treat conditions like Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia. The patent also includes methods for controlling these conditions. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights AbbVie Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Hif-1a prolyl hydroxylase inhibitors for treating cardiovascular diseases

Source: United States Patent and Trademark Office (USPTO). Credit: AbbVie Inc

A recently granted patent (Publication Number: US11883386B2) discloses a process for preparing a compound with a specific chemical formula. The process involves reacting certain compounds in a series of steps, including the use of a specific catalyst and base in the reaction. The patent claims detail the specific reagents and conditions required for the successful synthesis of the compound.

Furthermore, the patent claims specify the use of particular coupling reagents in the process, highlighting the importance of these components in the overall reaction. The inclusion of these details in the claims provides a clear and concise guide for researchers and practitioners in the field who may seek to replicate or build upon the disclosed process. Overall, the patent offers valuable insights into the preparation of the compound and sets a foundation for further research and development in this area of chemistry.

To know more about GlobalData’s detailed insights on AbbVie, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies